MCL
At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.
Autoimmune encephalitis and myelitis is increasingly recognized as a cause of CNS disease in children and teens. Andrew McKeon, M.B., B.Ch., M.D, gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
In this month’s “Hot Topic,” Sounak Gupta, M.B.B.S., Ph.D., discusses selecting tissues and other tissue considerations for molecular testing. He also reviews tissue metrics and requirements, which differ based on test platforms. It is important to keep in mind that the details of tissue metrics change over time as they continue to evolve with technology.
In December 2019, Mayo Clinic Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., talks about Mayo Clinic Laboratories’ serologic and molecular testing for the identification of infection with dengue virus. Dengue virus poses a significant public health threat worldwide. Rapid and accurate identification of the infection enables directed monitoring of patients who may be at increased risk of developing hemorrhagic fever of dengue shock syndrome.
Due to the Christmas holiday (recognized on Wednesday, December 25) and the New Year's holiday (recognized on Wednesday, January 1), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered.
In November 2019, Mayo Clinic Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.
Understanding the difference between benign and malignant adrenal tumors has always been difficult, but the new Urinary Steroid Profile assay will assist with this medical challenge.
Due to the Thanksgiving holiday in the United States (recognized on Thursday, Nov. 28), the Mayo Clinic Laboratories specimen pickup and delivery schedule will be altered. To ensure that your specimen vitality and turnaround time are not affected, plan ahead and note that no pickups or deliveries will be made on November 28 by our couriers or FedEx.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the over utilization of IgM serologic testing for herpes simplex virus and the recommendation by multiple agencies, including the CDC and the Infectious Diseases Society of America, to avoid using this test for clinical decision making purposes. As a result of these recommendations and data generated at Mayo Clinic, Dr. Theel will summarize why HSV IgM testing will no longer be offered through Mayo Clinic Laboratories.
In October 2019, Mayo Clinic Laboratories announced seven new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
This week's featured chromosomal microarray test in focus is presented by William Sukov, M.D., a pathologist and cancer geneticist at Mayo Clinic. He discusses when this test should be used for patients with renal tumors.
Hear advice firsthand from William Morice, II, M.D., Ph.D., Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, as he tells stories that helped shape his journey in laboratory medicine.